Basic Information
| LncRNA/CircRNA Name | LINC01537 |
| Synonyms | NA |
| Region | GRCh38_11:72570660-72573229 |
| Ensemble | ENSG00000227467 |
| Refseq | NR_126364 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin, tyrosine kinase inhibitor (TKI) nilotinib | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | Lung Cancer |
| ICD-0-3 | C34 |
| Methods | RNA-seq, qPCR |
| Sample | human lung cancer cell lines A549 and PC-9, cancerous and corresponding noncancer lung tissues |
| Expression Pattern | down-regulated |
| Function Description | Validation analysis confirmed the downregulation of LINC01537 in lung cancer. LINC01537 was observed to inhibit tumor growth and metastasis. It also increased cellular sensitivity to nilotinib. PDE2A (phosphodiesterase 2A) was further identified to be a target of LINC01537 and it was seen that LINC01537 promoted PDE2A expression via RNA-RNA interaction to stabilize PDE2A mRNA and thus echoed effects of PDE2A on energy metabolism including both Warburg effect and mitochondrial respiration. |
| Pubmed ID | 31374807 |
| Year | 2019 |
| Title | Analysis of Survival-Related lncRNA Landscape Identifies A Role for LINC01537 in Energy Metabolism and Lung Cancer Progression |
External Links
| Links for LINC01537 | GenBank HGNC NONCODE |
| Links for Lung Cancer | OMIM COSMIC |